Aclaris Therapeutics Added to Nasdaq Biotechnology Index Effective December 19, 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Should l Buy ACRS?
Source: Newsfilter
- Index Inclusion: Aclaris Therapeutics was added to the Nasdaq Biotechnology Index at the close of trading on December 19, 2025, marking a significant recognition in the biopharmaceutical sector that enhances its market image and investor confidence.
- Market Standards: The Nasdaq Biotechnology Index requires companies to meet minimum market capitalization and average daily trading volume standards, and Aclaris's inclusion reflects its stability and growth potential in the biopharmaceutical industry.
- R&D Strength: Aclaris focuses on developing novel product candidates for immuno-inflammatory diseases, boasting a multi-stage product pipeline that underscores its ongoing commitment to addressing patient needs.
- Investor Attention: Inclusion in the index may attract more institutional investors, potentially driving up the company's stock price and strengthening its competitive position in the biopharmaceutical market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACRS
Wall Street analysts forecast ACRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRS is 9.25 USD with a low forecast of 6.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.390
Low
6.00
Averages
9.25
High
16.00
Current: 3.390
Low
6.00
Averages
9.25
High
16.00
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aclaris ATI-2138 Shows Superior Efficacy in Hair Loss Treatment
- Preclinical Results: Aclaris Therapeutics' ATI-2138 demonstrated rapid and near-complete hair regrowth in a murine model, achieving 87% regrowth at week 4 compared to Pfizer's Litfulo at 48%, indicating a significant therapeutic advantage in treating autoimmune alopecia.
- Future Trial Plans: Aclaris is set to initiate a Phase 2b trial for ATI-2138 in the first half of 2026, exploring its potential for additional alopecia indications, reflecting the company's confidence in the drug's market prospects.
- Strong Stock Performance: ACRS shares are trading at $3.88, 22.6% above the 20-day simple moving average and have increased by 58.16% over the past year, showcasing robust short-term and medium-term momentum that suggests investor optimism about the company's future.
- Analyst Ratings: The stock carries a 'Buy' rating with an average price target of $10.73, while HC Wainwright & Co. maintains a target of $16, indicating strong market recognition of Aclaris' growth potential.
See More
Aclaris Therapeutics Added to Nasdaq Biotechnology Index Effective December 19, 2025
- Index Inclusion: Aclaris Therapeutics has been added to the Nasdaq Biotechnology Index effective December 19, 2025, marking a significant recognition in the biopharmaceutical sector that enhances its market image and investor confidence.
- Market Standards: The Nasdaq Biotechnology Index aims to track the performance of securities classified as biotechnology or pharmaceutical, and Aclaris's inclusion indicates it meets various eligibility criteria, including minimum market capitalization and average daily trading volume, thereby strengthening its competitive position in the industry.
- Annual Evaluation: The index is evaluated annually in December using a modified capitalization-weighted methodology, and Aclaris's addition may attract more investor attention, potentially improving its stock liquidity and market performance.
- R&D Potential: As a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, Aclaris's inclusion not only elevates its industry standing but may also bring additional funding support for its R&D pipeline, aiding in the development of new products to meet patient needs.
See More
Aclaris Therapeutics Added to Nasdaq Biotechnology Index
- Inclusion in Index: Aclaris Therapeutics (ACRS) has been added to the Nasdaq Biotechnology Index.
- Announcement Timing: The announcement regarding the inclusion was made late Friday.
See More
Aclaris Therapeutics Added to Nasdaq Biotechnology Index Effective December 19, 2025
- Index Inclusion: Aclaris Therapeutics was added to the Nasdaq Biotechnology Index at the close of trading on December 19, 2025, marking a significant recognition in the biopharmaceutical sector that enhances its market image and investor confidence.
- Market Standards: The Nasdaq Biotechnology Index requires companies to meet minimum market capitalization and average daily trading volume standards, and Aclaris's inclusion reflects its stability and growth potential in the biopharmaceutical industry.
- R&D Strength: Aclaris focuses on developing novel product candidates for immuno-inflammatory diseases, boasting a multi-stage product pipeline that underscores its ongoing commitment to addressing patient needs.
- Investor Attention: Inclusion in the index may attract more institutional investors, potentially driving up the company's stock price and strengthening its competitive position in the biopharmaceutical market.
See More
Reasons to Consider Aclaris Therapeutics (ACRS) as a Strong Momentum Stock: Is It Time to Buy?
Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation that they will continue to rise. The Zacks Momentum Style Score helps identify stocks with strong momentum characteristics.
Aclaris Therapeutics Performance: Aclaris Therapeutics (ACRS) has a Momentum Style Score of B and a Zacks Rank of #2 (Buy), with shares increasing 19.64% over the past quarter and 66.12% over the past year, outperforming the S&P 500.
Volume and Estimate Revisions: ACRS has an average 20-day trading volume of 1,004,293 shares, indicating bullish momentum. Additionally, recent earnings estimate revisions have been positive, contributing to its favorable consensus estimate.
Investment Recommendations: The article suggests Aclaris Therapeutics as a promising stock pick for investors looking for momentum opportunities, alongside other stocks identified by Zacks Investment Research that are expected to perform well in the near term.
See More
HC Wainwright & Co. Affirms Buy Rating for Aclaris Therapeutics, Keeps $16 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
See More
Aclaris ATI-2138 Shows Superior Efficacy in Hair Loss Treatment
- Preclinical Results: Aclaris Therapeutics' ATI-2138 demonstrated rapid and near-complete hair regrowth in a murine model, achieving 87% regrowth at week 4 compared to Pfizer's Litfulo at 48%, indicating a significant therapeutic advantage in treating autoimmune alopecia.
- Future Trial Plans: Aclaris is set to initiate a Phase 2b trial for ATI-2138 in the first half of 2026, exploring its potential for additional alopecia indications, reflecting the company's confidence in the drug's market prospects.
- Strong Stock Performance: ACRS shares are trading at $3.88, 22.6% above the 20-day simple moving average and have increased by 58.16% over the past year, showcasing robust short-term and medium-term momentum that suggests investor optimism about the company's future.
- Analyst Ratings: The stock carries a 'Buy' rating with an average price target of $10.73, while HC Wainwright & Co. maintains a target of $16, indicating strong market recognition of Aclaris' growth potential.
See More
Aclaris Therapeutics Added to Nasdaq Biotechnology Index Effective December 19, 2025
- Index Inclusion: Aclaris Therapeutics has been added to the Nasdaq Biotechnology Index effective December 19, 2025, marking a significant recognition in the biopharmaceutical sector that enhances its market image and investor confidence.
- Market Standards: The Nasdaq Biotechnology Index aims to track the performance of securities classified as biotechnology or pharmaceutical, and Aclaris's inclusion indicates it meets various eligibility criteria, including minimum market capitalization and average daily trading volume, thereby strengthening its competitive position in the industry.
- Annual Evaluation: The index is evaluated annually in December using a modified capitalization-weighted methodology, and Aclaris's addition may attract more investor attention, potentially improving its stock liquidity and market performance.
- R&D Potential: As a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, Aclaris's inclusion not only elevates its industry standing but may also bring additional funding support for its R&D pipeline, aiding in the development of new products to meet patient needs.
See More
Aclaris Therapeutics Added to Nasdaq Biotechnology Index
- Inclusion in Index: Aclaris Therapeutics (ACRS) has been added to the Nasdaq Biotechnology Index.
- Announcement Timing: The announcement regarding the inclusion was made late Friday.
See More
Aclaris Therapeutics Added to Nasdaq Biotechnology Index Effective December 19, 2025
- Index Inclusion: Aclaris Therapeutics was added to the Nasdaq Biotechnology Index at the close of trading on December 19, 2025, marking a significant recognition in the biopharmaceutical sector that enhances its market image and investor confidence.
- Market Standards: The Nasdaq Biotechnology Index requires companies to meet minimum market capitalization and average daily trading volume standards, and Aclaris's inclusion reflects its stability and growth potential in the biopharmaceutical industry.
- R&D Strength: Aclaris focuses on developing novel product candidates for immuno-inflammatory diseases, boasting a multi-stage product pipeline that underscores its ongoing commitment to addressing patient needs.
- Investor Attention: Inclusion in the index may attract more institutional investors, potentially driving up the company's stock price and strengthening its competitive position in the biopharmaceutical market.
See More
Reasons to Consider Aclaris Therapeutics (ACRS) as a Strong Momentum Stock: Is It Time to Buy?
Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation that they will continue to rise. The Zacks Momentum Style Score helps identify stocks with strong momentum characteristics.
Aclaris Therapeutics Performance: Aclaris Therapeutics (ACRS) has a Momentum Style Score of B and a Zacks Rank of #2 (Buy), with shares increasing 19.64% over the past quarter and 66.12% over the past year, outperforming the S&P 500.
Volume and Estimate Revisions: ACRS has an average 20-day trading volume of 1,004,293 shares, indicating bullish momentum. Additionally, recent earnings estimate revisions have been positive, contributing to its favorable consensus estimate.
Investment Recommendations: The article suggests Aclaris Therapeutics as a promising stock pick for investors looking for momentum opportunities, alongside other stocks identified by Zacks Investment Research that are expected to perform well in the near term.
See More
HC Wainwright & Co. Affirms Buy Rating for Aclaris Therapeutics, Keeps $16 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
See More
